Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and...
Investing.com - Artelo Biosciences (NASDAQ: ARTL) reported second quarter EPS of $-0.5600, $0.22 better than the analyst estimate of $-0.7750. Revenue for the quarter came in at $0.00...
Artelo Biosciences (NASDAQ:ARTL) has filed $75,000,000 mixed shelf of:Common StockPreferred StockDebt SecuritiesWarrantsUnits...
Artelo Biosciences (NASDAQ:ARTL), Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with...
An analyst from H.C. Wainwright maintained Artelo Biosciences (NASDAQ: ARTL) at 'buy' with a price target of $5.00 from a prior price target of %currency%%price%. Prior to this rating,...
Investing.com - Artelo Biosciences (NASDAQ: ARTL) reported third quarter EPS of $-0.7600, $0.38 better than the analyst estimate of $-1.1400. Revenue for the quarter came in at $0.00 versus...
Investing.com - Artelo Biosciences reported on Tuesday third quarter {{erl-1123098||earnings that beat analysts' forecasts and revenue that was inline with expectations. Artelo Biosciences...
Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Oil & Gas, Industrials and Basic Materials sectors propelled shares higher while losses in the Utilities,...
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Technology, Basic Materials and Industrials sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Consumer Services, Technology and Oil & Gas sectors propelled shares higher. At the close in NYSE, the...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
